Cybin Inc., a clinical-stage neuropsychiatry company, announced that Chief Medical Officer Amir Inamdar and Chief Business Officer George Tziras will participate in a fireside chat at TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit on September 17, 2025, at 9:20 a.m. ET. The presentation will focus on the company's development of next-generation treatment options for mental health conditions.
The company is developing CYB003, a proprietary deuterated psilocin analog currently in Phase 3 studies for adjunctive treatment of major depressive disorder. This investigational treatment has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, indicating its potential to address significant unmet medical needs. Additionally, Cybin is advancing CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in Phase 2 study for generalized anxiety disorder.
Cybin's research pipeline includes investigational compounds focused on 5-HT receptors, representing a novel approach to mental healthcare. The company, founded in 2019, maintains operations in Canada, the United States, the United Kingdom, and Ireland, positioning it as a global player in the neuropsychiatry space. Investors and industry observers can access the latest news and updates relating to CYBN through the company's newsroom at https://ibn.fm/CYBN.
The participation in this summit comes at a critical time for the psychedelic medicine industry, as regulatory pathways for novel mental health treatments continue to evolve. Cybin's clinical progress with psychedelic-derived compounds represents a significant shift in how mental health conditions might be treated in the future, moving beyond traditional pharmaceutical approaches. The company's work could potentially offer new hope for patients who have not responded to conventional treatments for depression and anxiety disorders.
The full press release detailing the executive participation can be viewed at https://ibn.fm/KXmrj. This presentation opportunity allows Cybin to showcase its clinical advancements to a specialized audience of investors, researchers, and healthcare professionals focused on novel neuropsychiatry mechanisms. The discussion may provide insights into the company's strategic direction and the broader implications of psychedelic-based therapies for mental healthcare.
